Figure 2.
Outcomes of patients according to hematologic recovery, MRD status, and subsequent HSCT. CIR (A), RFS (B), and OS (C) stratified according to CRMRD– vs lesser responses and HSCT vs no HSCT. Landmark analysis excluded patients who relapsed or died within 1.4 months from the time of response to salvage chemotherapy.

Outcomes of patients according to hematologic recovery, MRD status, and subsequent HSCT. CIR (A), RFS (B), and OS (C) stratified according to CRMRD– vs lesser responses and HSCT vs no HSCT. Landmark analysis excluded patients who relapsed or died within 1.4 months from the time of response to salvage chemotherapy.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal